Exelixis Inc Restructuring Costs
Exelixis Inc (EXEL) reported Restructuring Costs of -$5.32 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-10-30.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2013-10-30
- Exelixis Inc restructuring costs for the quarter ending 2013-09-30 was -$1.97M.
- Exelixis Inc restructuring costs for the quarter ending 2013-06-30 was -$971.00K.
- Exelixis Inc restructuring costs for the quarter ending 2013-03-31 was -$2.38M.
- Exelixis Inc restructuring costs for the quarter ending 2012-12-31 was $8.73M, a 143.73% increase year-over-year.
- Exelixis Inc restructuring costs for fiscal 2012 was $5.24M.
- Exelixis Inc restructuring costs for fiscal 2011 was -$303.00K, a 102.12% decline from fiscal 2010.
- Exelixis Inc restructuring costs for fiscal 2010 was $14.28M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2013-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | -$2.94M derived: sum of 2 quarters · filed 2013-10-30 | -$5.32M 10-Q · filed 2013-10-30 | $3.41M derived: sum of 4 quarters · filed 2013-10-30 |
| 2013-06-30 | -$971.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$3.35M 10-Q · filed 2013-08-06 | $5.38M derived: sum of 3 quarters · filed 2013-08-06 | $3.89M derived: sum of 4 quarters · filed 2013-10-30 |
| 2013-03-31 | -$2.38M 10-Q · filed 2013-05-07 | $6.36M derived: sum of 2 quarters · filed 2013-05-07 | $4.86M derived: sum of 3 quarters · filed 2013-10-30 | $4.73M derived: sum of 4 quarters · filed 2013-10-30 |
| 2012-12-31 | $8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $7.24M derived: sum of 2 quarters · filed 2013-10-30 | $7.11M derived: sum of 3 quarters · filed 2013-10-30 | $5.24M 10-K · filed 2013-02-21 |
| 2012-09-30 | -$1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | -$1.62M derived: sum of 2 quarters · filed 2013-10-30 | -$3.49M 10-Q · filed 2013-10-30 | $94.00K derived: sum of 4 quarters · filed 2013-10-30 |
| 2012-06-30 | -$130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$2.00M 10-Q · filed 2013-08-06 | $1.59M derived: sum of 3 quarters · filed 2013-08-06 | $1.88M derived: sum of 4 quarters · filed 2013-08-06 |
| 2012-03-31 | -$1.86M 10-Q · filed 2013-05-07 | $1.72M derived: sum of 2 quarters · filed 2013-05-07 | $2.01M derived: sum of 3 quarters · filed 2013-05-07 | -$690.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2011-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $3.88M derived: sum of 2 quarters · filed 2013-02-21 | $1.18M derived: sum of 3 quarters · filed 2013-02-21 | -$303.00K 10-K · filed 2013-02-21 |
| 2011-09-30 | $294.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$2.41M derived: sum of 2 quarters · filed 2012-11-07 | -$3.89M 10-Q · filed 2012-11-07 | $1.23M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | -$2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | -$4.18M 10-Q · filed 2012-08-02 | $932.00K derived: sum of 3 quarters · filed 2013-02-21 | -$1.03M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | -$1.48M 10-Q · filed 2012-05-03 | $3.63M derived: sum of 2 quarters · filed 2013-02-21 | $1.67M derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $3.15M derived: sum of 2 quarters · filed 2013-02-21 | $14.28M 10-K · filed 2013-02-21 | |
| 2010-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $9.17M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $11.13M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |